Hansoh Pharma Announces Application for Phase 3 Trial of Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC)
Shanghai, China — September 13, 2021— Hansoh Pharma (HKEX 3692.HK), an innovative biopharmaceutical company, carrying the mission of "create excellenc...
2021.09.13